Group 1 - I-Mab will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - The presentation will be led by Sean Fu, CEO, and Phillip Dennis, CMO [2] - One-on-one and small group meetings with management will take place on December 3-4, 2024 [2] Group 2 - I-Mab is a U.S.-based global biotech company focused on developing differentiated immunotherapies for cancer treatment [3] - The company has established operations in Rockville, Maryland, and Short Hills, New Jersey [3]

Core Insights - I-Mab is advancing its pipeline with promising data for its immunotherapy candidates, particularly uliledlimab and givastomig, as presented at major medical conferences [1][2][4][6] - The company appointed Dr. Sean Fu as the permanent CEO effective November 1, 2024, indicating a stable leadership transition [1][10] - I-Mab has a strong cash position of $184.4 million, expected to fund operations into 2027 [1][11] Pipeline Overview - Uliledlimab (CD73 antibody) is set to enter a randomized Phase 2 study in first-line metastatic non-small cell lung cancer (mNSCLC) in 1H 2025 [1][5] - Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) is undergoing a Phase 1b study in combination with nivolumab plus chemotherapy for first-line metastatic gastric cancer, with topline data expected in 2H 2025 [5][8] - Ragistomig (PD-L1 x 4-1BB bispecific antibody) is in ongoing Phase 1 studies for advanced solid tumors [8] Clinical Data Highlights - Phase 1 data for uliledlimab showed full target engagement and a positive correlation between overall response rate (ORR) and drug exposure in mNSCLC patients [4] - Givastomig demonstrated an ORR of 16.3% in gastric cancer patients, with a favorable safety profile and no dose-limiting toxicities [6][7] - The optimal monotherapy dose range for givastomig was defined as 8-12 mg/kg, with ongoing studies supporting this dosage [6][7] Financial Performance - Research and development expenses for Q3 2024 were $4.5 million, a decrease from $5.1 million in Q3 2023, attributed to streamlined clinical activities [13] - Administrative expenses increased to $7.9 million in Q3 2024 from $5.9 million in Q3 2023, primarily due to legal costs [14] - The net loss from continuing operations was $(20.5) million for Q3 2024, compared to $(8.2) million in Q3 2023 [16] Strategic Developments - A collaboration agreement with Sanofi for uliledlimab in Greater China includes initial and milestone payments totaling approximately €32 million, with potential for up to €213 million in success-based milestones [10] - The company settled approximately $15 million in repurchase obligations related to its China operations, resulting in a 15% ownership in TJ Bio post-settlement [10]

ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-M ...

Company Overview - I-Mab is a US-based global biotech company focused on developing highly differentiated immunotherapies for cancer treatment [3]. Financial Results Announcement - I-Mab plans to release its financial results for the third quarter ended September 30, 2024, on November 14, 2024, before the market opens [1]. - The company will not host a conference call to discuss the third quarter financial results [2]. Future Communications - I-Mab intends to hold an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives [2].

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting Date Thursday, November 7, 2024 Meetings One-on-one and small group meetings: November 7, 2024 Sean Fu, PhD ...

I-Mab Sponsored ADR (IMAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earning ...

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levelsThe recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study dosesA Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in fro ...

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025ROCKVILLE, Md., Sept. 10, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech com ...

I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET Company Participants Sean Fu - Chief Executive Officer (interim) Phillip Dennis - Chief Medical Officer Joseph Skelton - Chief Financial Officer Tyler Ehler - Vice President, Investor Relations Conference Call Participants Joe Catanzaro - Piper Sandler Unknown Analyst - Jefferies Andres Maldonado - HC Wainwright Operator Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conf ...

Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short- ...